Rhovac is open to all sale and partnership opportunities
The biotech company Rhovac has yet again initiated plans for a potential transaction – or a partnership. According to CEO Anders Månsson, the company is "ready for everything."
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
All paths are open when it comes to the biotech company Rhovac's journey foward. That is, as long as the results of the ongoing phase IIb trial with its lead candidate, RV001, which is a RhoC-based cancer vaccine, look promising, CEO at Rhovac Anders Månsson tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech begins phase III trial with partner MSD
For subscribers
Sanofi pays up to USD 1bn for new multiple myeloma therapy
For subscribers
.jpg&w=384&q=75)
